These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2349617)

  • 1. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E; Buemi AL; Sanz E; Bertilsson L
    Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
    Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
    Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Küpfer A; Preisig R
    Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
    Atiba JO; Blaschke TF; Wilkinson GR
    Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
    Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
    Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
    Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
    Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
    Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
    Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
    Alván G; Bechtel P; Iselius L; Gundert-Remy U
    Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.